Research Paper Volume 15, Issue 12 pp 5854—5872

Figure 3. iPSC-derived exosomes significantly improved BMC proliferation. (A) Quantification of the concentration of BMCs from old mice in different treatment groups. Cloned BMCs were digested and calculated at 4, 8, and 12 d after treatment. Old: BMCs of untreated old mice; Old + exo in vivo: BMCs of old mice pre-treated with iPSC-derived exosomes via tail vein injection; Old + exo in vitro: BMCs of old mice were cultured with iPSC-exosomes in vitro; Old + exo in vivo and exo in vitro: BMCs of old mice pre-treated with iPSC-derived exosomes via tail vein injection were cultured with iPSC-exosomes in vitro. (B) Quantification of the concentration of BMCs from young mice with different treatment groups. Cloned BMCs were digested and calculated 4, 8, and 12 d after treatment. Young: BMCs of untreated young mice; Young + exo in vivo: BMCs of young mice pre-treated with iPSC-derived exosomes via tail vein injection; Young + exo in vitro: BMCs of untreated young mice were cultured with iPSC-exosomes in vitro; Young + exo in vivo and exo in vitro: BMCs of young mice pre-treated with iPSC-derived exosomes via tail vein injection were cultured with iPSC-exosomes in vitro. iPSCs, induced pluripotent stem cells; exo, exosomes; BMCs, bone marrow stromal cell.